Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
J. Clin. Oncol 2022 Jun 23;[EPub Ahead of Print], JE Rosenberg, SH Park, V Kozlov, TV Dao, D Castellano, JR Li, SD Mukherjee, K Howells, H Dry, MC Lanasa, R Stewart, DF BajorinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.